Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (4): 361-364.
DOI: 10.19803/j.1672-8629.20230045

Previous Articles     Next Articles

Determination of meglumine in lansoprazole for injection by HPLC-NQAD

YANG Qian1, HUI Yanchun1, WANG Chen2#, ZHANG Xianhua3, XU Mingzhe2,*   

  1. 1Sanyo fine trading Co., LTD, Beijing 100022, China;
    2National Institutes for Food and Drug Control, Beijing 102629, China;
    3Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
  • Received:2023-02-03 Online:2023-04-15 Published:2023-04-20

Abstract: Objective To establish a method for determining the content of meglumine in lansoprazole for injection based on HPLC-NQAD. Methods The HPLC-NQAD method was established on a CAPCELL PAK CR 1:4 column(2.0 mm × 150 mm, 5 μm) by using a mobile phase of 5 mmol·L-1 ammonium formate-2% acetonitrile(A) and 50 mmol·L-1 ammonium formate-50% acetonitrile(B) under gradient elution at a flow rate of 0.3 mL·min-1. The column temperature was 40℃, injection volume was 5 μL, NQAD evaporation temperature was 35℃, atomization temperature was 30℃, and nitrogen pressure was 30 psi. Results Meglumine was separated completely in the test solution. The calibration curve was linear within the range of 1.0 µg·mL-1 to 100.0 µg·mL-1 for meglumine(r = 0.999 8). The average recovery was 99.96%, and the RSD was 1.01%. Conclusion This method has proved to be simple, accurate, sensitive and reliable. It can be used for the determination of meglumine in lansoprazole for injection.

Key words: HPLC-NQAD, lansoprazole, injection, meglumine, cosolvent, determination

CLC Number: